88IV - PR Newswire Asia's news


Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum SHANGHAI , Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, ... 2026-08-19T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion HONG KONG , Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP ... 2026-08-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product WUXI, China , Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY) , a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and ... 2026-08-19T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 VALBY, Denmark , Aug. 19, 2026 /PRNewswire/ -- Key highlights ... 2026-08-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Everest Medicines Announces Interim Results for First Half of 2026 SHANGHAI , Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, ... 2026-08-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a first-in-class anti-BCMA ADC, could transform treatment ... 2026-08-19T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit SHANGHAI and HONG KONG , Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ... 2026-08-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CARsgen Therapeutics Announces 2026 Interim Results SHANGHAI , Aug. 19, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Re ... 2026-08-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. Piramal has held a stake in Yapan Bio since ... 2026-08-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue ... 2026-08-18T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology